| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
133,930,000 |
| Market
Cap: |
28.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2103 - $0.2103 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Biocept is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid. Co. has commercialized its CNSide and Target Selector assays for detecting and characterizing various different carcinomas derived from epithelial cells of solid organs such as: breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. In addition, Co. has launched RT-PCR Coronavirus testing at its laboratory.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hale David F |
Director |
– • – |
2021-12-09 |
4 |
S |
$4.07 |
$289 |
D/D |
(71) |
796 |
|
57% |
|
| Hale David F |
Director |
– • – |
2021-12-09 |
4 |
S |
$4.06 |
$1,519 |
I/I |
(374) |
101 |
|
57% |
|
| Dugan Michael C |
Chief Med Off & Med. DirectorO |
• – – |
2020-08-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,700 |
|
-49% |
|
| Hale David F |
Director |
– • – |
2020-06-12 |
4 |
S |
$0.56 |
$309 |
D/D |
(556) |
867 |
|
18% |
|
| Hale David F |
Director |
– • – |
2020-06-12 |
4 |
S |
$0.55 |
$335 |
I/I |
(604) |
112 |
|
18% |
|
| Gerhardt Bruce |
Director |
– • – |
2018-01-30 |
4 |
B |
$0.00 |
$0 |
D/D |
25,000 |
98,303 |
2.31 |
- |
|
| Li Bin |
10% Owner |
– – • |
2017-08-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,147,667 |
|
- |
|
| Kennedy Timothy |
CFO, Sr V.P. Operations & Sec. |
• – – |
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
86,363 |
|
- |
|
| Arnold Lyle J |
SR VP of R&D and CSO |
• – – |
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
90,238 |
|
- |
|
| Nall Michael W. |
CEO & President |
• • – |
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
75,000 |
|
- |
|
| Singh Veena |
Sr VP & Sr Med Director |
• – – |
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
51,666 |
|
- |
|
| Terry Michael J |
Sr VP Comm. OperationsOfficer |
• – – |
2017-02-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,900 |
|
- |
|
| Li Bin |
10% Owner |
– – • |
2017-01-19 |
4 |
D |
$1.10 |
$280,382 |
D/D |
(254,893) |
0 |
|
- |
|
| Li Bin |
10% Owner |
– – • |
2017-01-18 |
4 |
D |
$1.10 |
$604,679 |
D/D |
(549,708) |
254,893 |
|
- |
|
| Li Bin |
10% Owner |
– – • |
2017-01-17 |
4 |
D |
$1.10 |
$964,039 |
D/D |
(876,399) |
804,601 |
|
- |
|
| Li Bin |
10% Owner |
– – • |
2016-10-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,681,000 |
|
- |
|
| Nall Michael W. |
CEO & President |
• • – |
2016-10-19 |
4 |
B |
$1.10 |
$39,999 |
I/I |
36,363 |
49,575 |
2.66 |
- |
|
| Gerhardt Bruce |
Director |
– • – |
2016-10-19 |
4 |
B |
$1.10 |
$55,000 |
D/D |
50,000 |
73,304 |
2.39 |
- |
|
| Kennedy Timothy |
CFO, Sr V.P. Operations & Sec. |
• – – |
2016-10-19 |
4 |
B |
$1.10 |
$39,999 |
D/D |
36,363 |
61,363 |
2.74 |
- |
|
| Chandler Marsha Alpert |
Director |
– • – |
2016-10-19 |
4 |
B |
$1.10 |
$5,000 |
D/D |
4,545 |
5,212 |
2.39 |
- |
|
| Huebner Bruce A |
Director |
– • – |
2016-10-19 |
4 |
B |
$1.10 |
$22,000 |
D/D |
20,000 |
24,000 |
2.39 |
- |
|
| Arnold Lyle J |
SR VP of R&D and CSO |
• – – |
2016-10-19 |
4 |
B |
$1.10 |
$49,500 |
D/D |
45,000 |
65,238 |
2.74 |
- |
|
| Singh Veena |
Sr VP & Sr Med Director |
• – – |
2016-10-19 |
4 |
B |
$1.10 |
$11,000 |
D/D |
10,000 |
26,666 |
2.74 |
- |
|
| Wilson Margaret Faye |
Director |
– • – |
2016-10-19 |
4 |
B |
$1.10 |
$15,000 |
D/D |
13,636 |
25,067 |
2.39 |
- |
|
| Reiss Claire |
10% Owner |
– – • |
2016-10-19 |
4 |
B |
$1.10 |
$249,999 |
I/I |
227,272 |
1,046,613 |
1.5 |
- |
|
83 Records found
|
|
Page 1 of 4 |
|
|
